Evaluation of 3-dimensional parametric analysis for the follow-up of malignant lesions in dynamic MR mammography under primary systemic therapy;Evaluierung der 3-dimensionalen parametrischen analyse in der MR-mammografie zur verlaufsbeurteilung maligner läsionen unter primär systemischer therapie

Geburtshilfe und Frauenheilkunde

Volumn 67, Issue 2, 2007, Pages 127-134

  Hauth, Elke A ^a   Oberhoff, C ^a   Jager H ^b   Maderwald, S ^a   Kimmig, R ^a   Forsting, M ^a  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b MARIEN HOSPITAL WESEL   (Germany)

Author keywords

Breast cancer; MR mammography; Primary systemic therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER THERAPY; CONTRAST ENHANCEMENT; FOLLOW UP; HISTOPATHOLOGY; HUMAN; IMAGE ANALYSIS; IMAGE QUALITY; MALIGNANT NEOPLASTIC DISEASE; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PARAMETER; SYSTEMIC THERAPY; THREE DIMENSIONAL IMAGING; TUMOR VOLUME;

EID: 34248648173     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-955979     Document Type: Article

References (29)

1. Kreienberg R, Kopp I, Lorenz W, Budach W, Dunst J et al. Qualitätssicherung in der Onkologie. Interdisziplinäre S3-Leitlinie für die Diagnostik und Therapie des Mammakarzinoms der Frau. Informationszentrum für Standards in der Onkologie (ISTO), Deutsche Krebsgesellschaft und Deutsche Gesellschaft für Gynäkologie und Geburtshilfe. München: Zuckerschwerdt Verlag, 2004
2. Regierer AC, Possinger K. Mammakarzinom. Manual Diagnostik und Therapie. Köln: Deutscher Ärzte-Verlag, 2005
3. Tumorzentrum München. Manual. Empfehlungen zur Diagnostik, Therapie und Nachsorge. Mammakarzinome. 10. Auflage. München: Zuckerschwerdt Verlag, 2005
4. Booser DJ, Hortobagyi GN. Treatment of locally advanced breast cancer. Semin Oncol 1992; 19: 278-285
5. Padhani AR, Hayes C, Assersohn L, Powles T, Makris A, Suckling J, Leach MO, Husband JE. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 2006; 239: 361-374
6. Fisher B, Bryant J, Wolmark N, Mamounas E, Brown A, Fisher ER, Wickerham DL, Begovic M, DeCillis A, Robidoux A, Margolese RG, Cruz AB Jr., Hoehn JL, Lees AW, Dimitrov NV, Bear HD. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685
7. Kaufmann M, Jonat W, Eiermann W, Costa S, Hilfrich J, Janicke F, Beckmann MW, Wallwiener D, Gerber B, Rody A, Schneeweiss A, Nitz U, Kohler U, von Minckwitz G. Systemische Therapie operabler Mamma-Karzinome. Zentralbl Gynakol 2005; 127: 207-212
8. Chollet P, Amat S, Cure H, de Latour M, Le Bouedec G, Mouret-Reynier MA, Ferriere JP, Achard JL, Dauplat J, Penault-Llorca F. Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer. Br J Cancer 2002; 86: 1041-1046
9. Segel MC, Paulus DD, Hortobagyi GN. Advanced primary breast cancer: assessment at mammography of response to induction chemotherapy. Radiology 1988; 169: 49-54
10. Weatherall PT, Evans GF, Metzger GJ, Saborrian MH, Leitch AM. MRI vs. histologic measurement of breast cancer following chemotherapy: comparison with x-ray mammography and palpation. J Magn Reson Imaging 2001; 13: 868-875
11. Londero V, Bazzocchi M, Del Frate C, Puglisi F, Di Loreto C, Francescutti G, Zuiani C. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy. Eur Radiol 2004; 14: 1371-1379
12. Rosen EL, Blackwell KL, Baker JA, Soo MS, Bentley RC, Yu D, Samulski TV, Dewhirst MW. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. AJR Am J Roentgenol 2003; 181: 1275-1282
13. Drew PJ, Kerin MJ, Mahapatra T, Malone C, Monson JR, Turnbull LW, Fox JN. Evaluation of response to neoadjuvant chemoradiotherapy for locally advanced breast cancer with dynamic contrast-enhanced MRI of the breast. Eur J Surg Oncol 2001; 27: 617-620
14. Wasser K, Klein SK, Junkermann H, Sinn HP, Darai S, Neff W, Kauczor HU, Delorme S. Neoadjuvante Chemotherapie des Mammakarzinoms. Welche posttherapeutischen (präoperativen) Informationen liefert die quantitative dynamische MRT? Radiologe 2005; [Epub ahead of print] DOI: 10.1007/s00117-005- 1303-1
15. Junkermann H, von Fournier D. Bildgebende Verfahren zur Beurteilung des Ansprechens des Mammakarzinoms auf eine präoperative Chemotherapie. Radiologe 1997; 37: 726-732
16. Degani H, Gusis V, Weinstein D, Fields S, Strano S. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nat Med 1997; 3: 780-782
17. Furman-Haran E, Grobgeld D, Kelcz F, Degani H. Critical role of spatial resolution in dynamic contrast-enhanced breast MRI. J Magn Reson Imaging 2001; 13: 862-867
18. Kelcz F, Furman-Haran E, Grobgeld D, Degani H. Clinical testing of high-spatial-resolution parametric contrast-enhanced MR imaging of the breast. AJR Am J Roentgenol 2002; 179: 1485-1492
19. Hauth EAM, Stockamp C, Maderwald S, Mühler A, Kimmig R, Jaeger H, Barkhausen J, Forsting M. Evaluation of the three-time-point method for diagnosis of breast lesions in contrast-enhanced MR mammography. Clinical Imaging 2006; 30: 160-165
20. Tofts PS, Berkowitz B, Schnall MD. Quantitative analysis of dynamic Gd-DTPA enhancement in breast tumors using a permeability model. Magn Reson Med 1995; 33: 564-568
21. Furman-Haran E, Degani H. Parametric analysis of breast MRI. J Comput Assist Tomogr 2002; 26: 376-386
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216
23. Sinn HP, Schmid H, Junkermann H, Huober J, Leppien G, Kaufmann M, Bastert G, Otto HF. Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtsh Frauenheilk 1994; 54: 552-558
24. Hauth EA, Stattaus J, Forsting M. Vergleich uni- und bidimensionaler Messverfahren zur Beurteilung des Therapieansprechens bei der Behandlung solider Tumoren. Radiologe 2006; [Epub ahead of print] DOI: 10.1007/s00117-005-1329-4
25. Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Tripathy D, Wolverton DS, Rugo HS, Hwang ES, Ewing CA, Hylton NM. MRI measurements of breast tumor volume predict response to neoadjuvant chemotherapy and recurrence-free survival. AJR Am J Roentgenol: 2005; 184: 1774-1781
26. El Khoury C, Servois V, Thibault F, Tardivon A, Ollivier L, Meunier M, Allonier C, Neuenschwander S. MR quantification of the washout changes in breast tumors under preoperative chemotherapy: feasibility and preliminary results. AJR Am J Roentgenol 2005; 184: 1499-1504
27. Makris A, Powles TJ, Kakolyris S, Dowsett M, Ashley SE, Harris AL. Reduction in angiogenesis after neoadjuvant chemoendocrine therapy in patients with operable breast carcinoma. Cancer 1999; 85: 1996-2000
28. Furman-Haran E, Schechtman E, Kelcz F, Kirshenbaum K, Degani H. Magnetic resonance imaging reveals functional diversity of the vasculature in benign and malignant breast lesions. Cancer 2005; 104: 708-718
29. Wasser K, Sinn HP, Fink C, Klein SK, Junkermann H, Ludemann HP, Zuna I, Delorme S. Accuracy of tumor size measurement in breast cancer using MRI is influenced by histological regression induced by neoadjuvant chemotherapy. Eur Radiol 2003; 13: 1213-1223